Stocklytics Platform
Asset logo for symbol HEPA
Hepion Pharmaceuticals
HEPA42
$0.49arrow_drop_down0.18%-$0.00
Penny Stock
Asset logo for symbol HEPA
HEPA42

$0.49

arrow_drop_down0.18%

Performance History

Chart placeholder
Key Stats
Open$0.49
Prev. Close$0.49
EPS-4.40
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.44M
PE Ratio-
LOWHIGH
Day Range0.49
0.49
52 Week Range0.35
5.31
Ratios
Revenue-
EBITDA Margin %-
EPS-4.40

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Hepion Pharmaceuticals (HEPA)

Hepion Pharmaceuticals Inc. (HEPA) is a pharmaceutical company focused on the development of targeted therapies for liver diseases. The company's lead drug candidate, CRV431, is being evaluated for the treatment of various liver diseases, including non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). CRV431 has shown promising results in preclinical and early clinical studies, demonstrating its potential to reduce liver fibrosis and inflammation.
Hepion Pharmaceuticals Inc. aims to address the significant unmet medical needs in liver diseases through innovative research and development. The company utilizes a smart analysis approach, leveraging advanced technologies and scientific expertise to identify novel therapeutic targets and develop effective treatments for liver diseases. By focusing on liver-specific molecular targets, Hepion Pharmaceuticals Inc. aims to develop therapies with improved efficacy and safety profiles.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.
Headquarters
Edison
Employees
25
Exchange
NASDAQ
add Hepion Pharmaceuticals  to watchlist

Keep an eye on Hepion Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Hepion Pharmaceuticals 's (HEPA) price per share?

The current price per share for Hepion Pharmaceuticals (HEPA) is $0.5. The stock has seen a price change of -$0 recently, indicating a -0.18% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Hepion Pharmaceuticals (HEPA)?

For Hepion Pharmaceuticals (HEPA), the 52-week high is $5.31, which is 970.56% from the current price. The 52-week low is $0.35, the current price is 41.71% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Hepion Pharmaceuticals (HEPA) a growth stock?

Hepion Pharmaceuticals (HEPA) has shown an average price growth of -5.34% over the past three years. It has received a score of -4 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Hepion Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Hepion Pharmaceuticals (HEPA) stock price performance year to date (YTD)?

As of the latest data, Hepion Pharmaceuticals (HEPA) has a year-to-date price change of -84.25%. Over the past month, the stock has experienced a price change of -25.98%. Over the last three months, the change has been -28.12%. Over the past six months, the figure is -53.21%. Looking at a longer horizon, the five-year price change stands at -99.55%.
help

Is Hepion Pharmaceuticals (HEPA) a profitable company?

Hepion Pharmaceuticals (HEPA) has a net income of -$48.93M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$48.45M. Furthermore, the EBITDA is -$31.51M.
help

What is the market capitalization of Hepion Pharmaceuticals (HEPA)?

Hepion Pharmaceuticals (HEPA) has a market capitalization of $3.44M. The average daily trading volume is 0.5, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level